Full Study Name
IMPACT – Identification of Men with a genetic predisposition to Prostate Cancer
Royal Marsden Hospital, Sutton, Surrey
Local Principal Investigator
Professor Gareth Evans
Recruiting – Men with Lynch Syndrome
Prostate cancer is the second most common cancer in men in the UK (after lung cancer) with 1 in 9 developing prostate cancer within their lifetime. Studies have indicated that men with Lynch Syndrome may be more susceptible to prostate cancer than men without an alteration. At present it is not clear how much increase in risk for prostate cancer the lynch syndrome gene alterations may confer. One of the aims of this study is to determine exactly what the risk of prostate cancer is for these men.
- Male carrier of a known pathogenic mutation* thought to confer a higher risk of prostate cancer
- Male who has tested negative for a known pathogenic mutation, thought to confer a higher risk of prostate cancer, within their family
- Age 40-69 years
- WHO performance status 0-2 (see Appendix B)
- No previous history of prostate cancer
- No previous prostate biopsy for raised PSA
- Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule.
- Informed written consent must be sought according to ICH/EU GCP, and national/local regulations before subject registration.
- In some centres ( including Manchester), a man can take part if he does not want to have genetic testing, where there is a mutation in his family. However, he must be aware that the data centre will test his DNA sample in order to establish his status.
- Previous cancer with a terminal prognosis of less than five years.
- Previous prostate cancer
International Study – many Collaborators.
UK Coordinating Centre – Royal Marsden Hospital, Sutton, Surrey.
Other UK sites – Birmingham, Newcastle, Exeter, Cambridge, Glasgow, Liverpool, Southampton and Leicester.
For more information click here